Clinical trial
Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized…
NCT00727194 · Alexion Pharmaceuticals, Inc., Industry · Terminated
Key facts
| NCT number | NCT00727194 |
|---|---|
| Title | Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis |
| Official title | A Randomized, Double-Blind, Placebo-Controlled, Cross-Over, Multi-Center Study of Eculizumab in Patients With Generalized Myasthenia Gravis (gMG) Who Have Moderate to Severe Muscle Weakness Despite Treatment With Immunosuppressants |
| Lead sponsor | Alexion Pharmaceuticals, Inc., Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Myasthenia Gravis |
| Intervention type | Drug |
| Interventions | eculizumab, Placebo |
| Enrollment | 14 |
| Start date | Oct 1, 2008 |
| Primary completion | Mar 1, 2011 |
| Completion | Jul 1, 2011 |
| First posted | Aug 1, 2008 |
| Last update posted | Sep 24, 2019 |
| Countries | Canada, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: